Now showing items 21-40 of 4775

    • The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin 

      Krastev, DB; Li, S; Sun, Y; Wicks, AJ; Hoslett, G; Weekes, D; Badder, LM; Knight, EG; Marlow, R; Pardo, MC; Yu, L; Talele, TT; Bartek, J; Choudhary, JS; Pommier, Y; Pettitt, SJ; Tutt, ANJ; Ramadan, K; Lord, CJ
      <jats:title>Abstract</jats:title><jats:p>Poly (ADP-ribose) polymerase (PARP) inhibitors elicit antitumour activity in homologous recombination-defective cancers by trapping PARP1 in a chromatin-bound state. How cells process ...
    • TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer 

      Beatson, RE; Parente-Pereira, AC; Halim, L; Cozzetto, D; Hull, C; Whilding, LM; Martinez, O; Taylor, CA; Obajdin, J; Luu Hoang, KN; Draper, B; Iqbal, A; Hardiman, T; Zabinski, T; Man, F; de Rosales, RTM; Xie, J; Aswad, F; Achkova, D; Joseph, C-YR; Ciprut, S; Adami, A; Roider, HG; Hess-Stumpp, H; Győrffy, B; Quist, J; Grigoriadis, A; Sommer, A; Tutt, ANJ; Davies, DM; Maher, J
    • Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study 

      Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; Boos, LA; Rzeniewicz, K; Gordon, W; Shum, B; Gerard, CL; Ward, B; Xie, W; Schmitt, AM; Joharatnam-Hogan, N; Cornish, GH; Pule, M; Mekkaoui, L; Ng, KW; Carlyle, E; Edmonds, K; Rosario, LD; Sarker, S; Lingard, K; Mangwende, M; Holt, L; Ahmod, H; Stone, R; Gomes, C; Flynn, HR; Agua-Doce, A; Hobson, P; Caidan, S; Howell, M; Wu, M; Goldstone, R; Crawford, M; Cubitt, L; Patel, H; Gavrielides, M; Nye, E; Snijders, AP; MacRae, JI; Nicod, J; Gronthoud, F; Shea, RL; Messiou, C; Cunningham, D; Chau, I; Starling, N; Turner, N; Welsh, L; van As, N; Jones, RL; Droney, J; Banerjee, S; Tatham, KC; Jhanji, S; O’Brien, M; Curtis, O; Harrington, K; Bhide, S; Bazin, J; Robinson, A; Stephenson, C; Slattery, T; Khan, Y; Tippu, Z; Leslie, I; Gennatas, S; Okines, A; Reid, A; Young, K; Furness, AJS; Pickering, L; Gandhi, S; Gamblin, S; Swanton, C; Nicholson, E; Kumar, S; Yousaf, N; Wilkinson, KA; Swerdlow, A; Harvey, R; Kassiotis, G; Larkin, J; Wilkinson, RJ; Turajlic, S
      <jats:title>Abstract</jats:title><jats:p>Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. ...
    • Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). 

      Popat, S; Liu, G; Lu, S; Song, G; Ma, X; Yang, JC-H
      Crizotinib is highly efficacious and more tolerable than chemotherapy for ALK<sup>+</sup> non-small-cell lung cancer (NSCLC), but its progression-free survival benefit and intracranial efficacy have limitations. Head-to-head ...
    • A Review of Breast Cancer Risk Factors in Adolescents and Young Adults. 

      McVeigh, UM; Tepper, JW; McVeigh, TP (2021-11-05)
      Cancer in adolescents and young adults (AYAs) deserves special consideration for several reasons. AYA cancers encompass paediatric malignancies that present at an older age than expected, or early-onset of cancers that are ...
    • A Review of High-Intensity Focused Ultrasound in Urology. 

      Cranston, D; Leslie, T; Ter Haar, G (2021-11-14)
      This review provides an introduction to high-intensity focused ultrasound (HIFU) and reviews its historical and current use in urological surgery. Current and historical literature (1927-2020), including that describing ...
    • EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma 

      Pacini, L; Cabal, VN; Hermsen, MA; Huang, PH
      Recurrent epidermal growth factor receptor (EGFR)-activating mutations have been identified in a rare form of head and neck cancer known as sinonasal squamous cell carcinoma (SNSCC), a malignant disease with a 5-year ...
    • Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment 

      Pasha, N; Turner, NC (NATURE PORTFOLIO, 2021-07-19)
    • Non-randomised comparison of efficacy and side effects of bicalutamide compared with LHRH analogues in combination with radiotherapy in the CHHiP trial. 

      Tree, A; Griffin, C; Syndikus, I; Birtle, A; Choudhury, A; Graham, J; Ferguson, C; Khoo, V; Malik, Z; O'Sullivan, J; Panades, M; Parker, C; Rimmer, Y; Scrase, C; Staffurth, J; Dearnaley, D; Hall, E
    • Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma 

      Millard, T; Chau, I; Iyengar, S; El‐Sharkawi, D; Cunningham, D; Sharma, B
    • Genetic Variation in <i>ABCC4</i> and <i>CFTR</i> and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia. 

      Bartram, T; Schütte, P; Möricke, A; Houlston, RS; Ellinghaus, E; Zimmermann, M; Bergmann, A; Löscher, B-S; Klein, N; Hinze, L; Junk, SV; Forster, M; Bartram, CR; Köhler, R; Franke, A; Schrappe, M; Kratz, CP; Cario, G; Stanulla, M (2021-10-20)
      Background Acute pancreatitis (AP) is a serious, mechanistically not entirely resolved side effect of L-asparaginase-containing treatment for acute lymphoblastic leukemia (ALL). To find new candidate variations for AP, we ...
    • Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. 

      Hastie, KM; Li, H; Bedinger, D; Schendel, SL; Dennison, SM; Li, K; Rayaprolu, V; Yu, X; Mann, C; Zandonatti, M; Diaz Avalos, R; Zyla, D; Buck, T; Hui, S; Shaffer, K; Hariharan, C; Yin, J; Olmedillas, E; Enriquez, A; Parekh, D; Abraha, M; Feeney, E; Horn, GQ; CoVIC-DB team1; Aldon, Y; Ali, H; Aracic, S; Cobb, RR; Federman, RS; Fernandez, JM; Glanville, J; Green, R; Grigoryan, G; Lujan Hernandez, AG; Ho, DD; Huang, K-YA; Ingraham, J; Jiang, W; Kellam, P; Kim, C; Kim, M; Kim, HM; Kong, C; Krebs, SJ; Lan, F; Lang, G; Lee, S; Leung, CL; Liu, J; Lu, Y; MacCamy, A; McGuire, AT; Palser, AL; Rabbitts, TH; Rikhtegaran Tehrani, Z; Sajadi, MM; Sanders, RW; Sato, AK; Schweizer, L; Seo, J; Shen, B; Snitselaar, JL; Stamatatos, L; Tan, Y; Tomic, MT; van Gils, MJ; Youssef, S; Yu, J; Yuan, TZ; Zhang, Q; Peters, B; Tomaras, GD; Germann, T; Saphire, EO
      [Figure: see text].
    • A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. 

      Bancroft, EK; Page, EC; Brook, MN; Thomas, S; Taylor, N; Pope, J; McHugh, J; Jones, A-B; Karlsson, Q; Merson, S; Ong, KR; Hoffman, J; Huber, C; Maehle, L; Grindedal, EM; Stormorken, A; Evans, DG; Rothwell, J; Lalloo, F; Brady, AF; Bartlett, M; Snape, K; Hanson, H; James, P; McKinley, J; Mascarenhas, L; Syngal, S; Ukaegbu, C; Side, L; Thomas, T; Barwell, J; Teixeira, MR; Izatt, L; Suri, M; Macrae, FA; Poplawski, N; Chen-Shtoyerman, R; Ahmed, M; Musgrave, H; Nicolai, N; Greenhalgh, L; Brewer, C; Pachter, N; Spigelman, AD; Azzabi, A; Helfand, BT; Halliday, D; Buys, S; Ramon Y Cajal, T; Donaldson, A; Cooney, KA; Harris, M; McGrath, J; Davidson, R; Taylor, A; Cooke, P; Myhill, K; Hogben, M; Aaronson, NK; Ardern-Jones, A; Bangma, CH; Castro, E; Dearnaley, D; Dias, A; Dudderidge, T; Eccles, DM; Green, K; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lilja, H; Lindeman, GJ; Lubinski, J; Axcrona, K; Mikropoulos, C; Mitra, AV; Moynihan, C; Ni Raghallaigh, H; Rennert, G; Collier, R; IMPACT Study Collaborators; Offman, J; Kote-Jarai, Z; Eeles, RA (2021-10-19)
      Background Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and ...
    • A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. 

      Collins, GP; Eyre, TA; Schmitz-Rohmer, D; Townsend, W; Popat, R; Giulino-Roth, L; Fields, PA; Krasniqi, F; Soussain, C; Stathis, A; Andjelkovic, N; Cunningham, D; Mandic, D; Radulovic, S; Tijanic, I; Horowitz, NA; Kurtovic, S; Schorb, E; Schmidt, C; Dimitrijević, S; Dreyling, M
      Bimiralisib is an orally bioavailable pan-phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the ...
    • Automatic Segmentation of Pelvic Cancers Using Deep Learning: State-of-the-Art Approaches and Challenges. 

      Kalantar, R; Lin, G; Winfield, JM; Messiou, C; Lalondrelle, S; Blackledge, MD; Koh, D-M (2021-10-22)
      The recent rise of deep learning (DL) and its promising capabilities in capturing non-explicit detail from large datasets have attracted substantial research attention in the field of medical image processing. DL provides ...
    • A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. 

      Fox, CP; Ali, AS; McIlroy, G; Thust, S; Martinez-Calle, N; Jackson, AE; Hopkins, LM; Thomas, CM; Kassam, S; Wright, J; Chaganti, S; Smith, J; Chau, I; Culligan, D; Linton, KM; Collins, GP; Ferreri, AJM; Lewis, D; Davies, AJ; Johnson, R; Auer, DP; Cwynarski, K
      Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a ...
    • The clinical utility of polygenic risk scores for multiple myeloma 

      Sud, A; Went, M; Law, P; Kaiser, M; Houlston, R
    • USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. 

      Ruiz, EJ; Pinto-Fernandez, A; Turnbull, AP; Lan, L; Charlton, TM; Scott, HC; Damianou, A; Vere, G; Riising, EM; Da Costa, C; Krajewski, WW; Guerin, D; Kearns, JD; Ioannidis, S; Katz, M; McKinnon, C; O'Connell, J; Moncaut, N; Rosewell, I; Nye, E; Jones, N; Heride, C; Gersch, M; Wu, M; Dinsmore, CJ; Hammonds, TR; Kim, S; Komander, D; Urbe, S; Clague, MJ; Kessler, BM; Behrens, A (2021-10-12)
      Lung squamous cell carcinoma (LSCC) is a considerable global health burden, with an incidence of over 600,000 cases per year. Treatment options are limited, and patient's 5-year survival rate is less than 5%. The ...
    • Diagnostic radiological examinations and risk of intracranial tumours in adults-findings from the Interphone Study. 

      Auvinen, A; Cardis, E; Blettner, M; Moissonnier, M; Sadetzki, S; Giles, G; Johansen, C; Swerdlow, A; Cook, A; Fleming, S; Berg-Beckhoff, G; Iavarone, I; Parent, M-E; Woodward, A; Tynes, T; McBride, M; Krewski, D; Feyching, M; Takebayashi, T; Armstrong, B; Hours, M; Siemiatycki, J; Lagorio, S; Larsen, SB; Schoemaker, M; Klaeboe, L; Lönn, S; Schüz, J; and the INTERPHONE study group (2021-10-14)
      Background Exposure to high doses of ionizing radiation is among the few well-established brain tumour risk factors. We used data from the Interphone study to evaluate the effects of exposure to low-dose radiation from ...
    • MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis 

      Zhao, H; Pomicter, AD; Eiring, AM; Franzini, A; Ahmann, J; Hwang, J-Y; Senina, AV; Helton, B; Iyer, SM; Yan, D; Khorashad, JS; Zabriskie, MS; Agarwal, A; Redwine, HM; Bowler, AD; Clair, PM; McWeeney, SK; Druker, BJ; Tyner, JW; Stirewalt, DL; Oehler, VG; Varambally, S; Berrett, KC; Vahrenkamp, JM; Gertz, J; Varley, KE; Radich, J; Deininger, MW
      The chronic phase of chronic myeloid leukemia (CP-CML) is characterized by excessive production of maturating myeloid cells. As CML stem/progenitor cells (LSPCs) are poised to cycle and differentiate, LSPCs must balance ...